Study of Metatinib Tromethamine Tablet
A Phase Ib Clinical Study of the Tolerance, Safety and Preliminary Efficacy Observation of Single-/Multiple- Doses of Metatinib Tromethamine Tablets in Patients With Advanced or Metastatic Solid Tumor
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Verwacht)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Shuangling Deng, MS
- Telefoonnummer: 86-025-85560000
- E-mail: dengshuangling@simcere.com
Studie Locaties
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Werving
- The First Bethune Hospital of Jilin University
-
Contact:
- Yanhua Ding, MD
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Werving
- West China Hospital, Sichuan University
-
Contact:
- Feng Bi, MD
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Werving
- The First Affiliated Hospital, Zhejiang University
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients with advanced or metastatic gastric cancer or colorectal cancer who progress after second-line therapy or the above treatment protocol, or patients with advanced or metastatic hepatocellular carcinoma who progress after first-line chemotherapy, interventional therapy or targeted therapy shall be verified by histology or cytology; or patients with advanced or metastatic non-squamous non-small cell lung cancer who cannot be operated or fail to first-line therapy shall be verified by histology or cytology;
- MET gene amplification or protein overexpression(IHC ≥2+),or exon-14 skipping;
- At least one measurable lesion (RECIST 1.1 );
- At least 4 weeks from the last chemotherapy, radiotherapy or anti-tumor biological products treatment; at least 8 weeks from the last anti-tumor antibody products treatment; at least 6 weeks from the last dose of nitrosourea, mitomycin C or doxorubicin;
- At least 4 weeks from major surgery or trauma, and the wound should fully heal; at least 1 week from minor surgery or trauma (i.e. tissue biopsy or fine needle aspiration);
- Toxicity from previous treatment has to restore to ≤ grade 1, baseline or irreversible (NCI CTC4.0);
- ECOG performance status 0-1;
- Life expectancy ≥3 months;
- Adequate hematologic function: ANC≥1.5×10^9 /L, HB≥90g/L(blood transfusion allowed), PLT≥100×10^9/L;
- Adequate hepatic function: ALT≤3×ULN, AST≤3×ULN, TBIL≤2×ULN(patients with liver metastases or liver cancer ALT≤5×ULN, AST≤5×ULN, TBIL≤2×ULN), Child-Pugh score≤7;
- Adequate renal function: uric acid<500μmol/L, creatinine<1.7mg/dL, proteinuria≤2+or≤2g/24h , GFR≥60 ml/min/1.73m^2;
- PT-INR/APTT≤1.5×ULN, Serum sodium, potassium, calcium, magnesium levels ≤1×ULN(NCI-CTC 4.0);
- Patients signed written informed consent;
- Willingness and capability to comply with protocol requirement and well communicate with investigators.
Exclusion Criteria:
- Severe, uncontrolled medical disorders or active infection, including but not limited to HIV antibody positive, active tuberculosis, HBV DNA copies>10^3/ml;
- Subjects have known or suspected brain metastases;
- Patients must receive other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for palliative local radiation) or traditional Chinese medicine for treatment of cancer during the study;
- Previously received other VEGF/VEGFR small-molecule inhibitors or antibodies therapy, including but not limited to Bevacizumab, Ramucirumab, Aflibercept;
- Previously received other HGF/c-Met small-molecule inhibitors or antibodies therapy, including but not limited to Crizotinib, Cabozantinib, Volitinib, Capmatinib (INC280), BPI-9016M;
- Imaging showed involvement of major blood vessels or nerves by tumor;
- Uncontrolled hypertension (systolic blood pressure>150mmHg and/or diastolic blood pressure>100mmHg after treatment);
- LVEF<50%;
- Apparent heart disease, including congestive heart failure(NYHA III-IV), history of myocardial infarction, or uncontrolled angina within 6 months prior to enrollment;
- Arrhythmias need to be treated, including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia or ventricular fibrillation; ECG abnormalities confirmed, including QT interval prolongation (males>450msec, females>470 msec);
- History of hemorrhagic or thrombotic events within 6 months before enrollment, i.e. cerebrovascular accidents(including TIA), pulmonary embolism, spontaneous hemorrhage of tumor;
- Patients need surgery within 28 days, or is expected to require surgery within 28 days after the last dose;
- Uncontrolled cavity effusion, such as large amount of pleural effusion and ascites;
- Gastrointestinal illnesses(i.e., uncontrolled diarrhea or malabsorption) at screening or within 3 months that may affect drug absorption;
- History or suspicious signs of gastrointestinal perforation;
- Concomitant medications that may affect the drug metabolism (i.e. strong CYP3A4 inhibitors or inducer );
- Pregnant or lactating women;
- Subjects of childbearing refused to use medically acceptable methods of contraception until 3 months after the last dose;
- Participate in other clinical trials within 4 weeks prior to enrollment;
- The investigators consider the patients are not suitable for this trial
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Metatinib Tromethamine
|
Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
incidence of adverse events
Tijdsspanne: until 30 days after the last dose
|
until 30 days after the last dose
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Objective response rate
Tijdsspanne: every 6 weeks, up to 2 years
|
every 6 weeks, up to 2 years
|
|
Disease control rate
Tijdsspanne: every 6 weeks, up to 2 years
|
every 6 weeks, up to 2 years
|
|
Progression free survival
Tijdsspanne: every 6 weeks, up to 2 years
|
every 6 weeks, up to 2 years
|
|
Overall survival
Tijdsspanne: every 6 weeks, up to 2 years
|
every 6 weeks, up to 2 years
|
|
Cmax for Metatinib
Tijdsspanne: day 1,day 2,day 8,day15,day22
|
day 1,day 2,day 8,day15,day22
|
|
Cmin for Metatinib
Tijdsspanne: day 1,day 2,day 8,day15,day22
|
day 1,day 2,day 8,day15,day22
|
|
Tmax for Metatinib
Tijdsspanne: day 1,day 2,day 8,day15,day22
|
day 1,day 2,day 8,day15,day22
|
|
AUC for Metatinib
Tijdsspanne: day 1,day 2,day 8,day15,day22
|
day 1,day 2,day 8,day15,day22
|
|
T1/2 for Metatinib
Tijdsspanne: day 1,day 2,day 8,day15,day22
|
day 1,day 2,day 8,day15,day22
|
|
CL for Metatinib
Tijdsspanne: day 1,day 2,day 8,day15,day22
|
day 1,day 2,day 8,day15,day22
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Feng Bi, MD, West China Hospital
Studie record data
Bestudeer belangrijke data
Studie start
Studie start
Primaire voltooiing (Verwacht)
Primaire voltooiing
Studie voltooiing (Verwacht)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- SIM-128-I-02
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .